Company Overview of Claris Lifesciences Limited
Claris Lifesciences Limited, together with its subsidiaries, manufactures and sells drugs and pharmaceuticals worldwide. It manufactures and markets products for anesthesia and analgesics, blood products, anti-infectives, plasma volume expanders, critical care, and nephrology areas, as well as for infusion therapy and nutrition applications. The company also provides dialysis and transplant range across systems, solutions, medicines, disposables, and equipment. In addition, it offers injectables for various therapeutic groups, including anti-emetics, CNS, cardiology, anti-malaria, haematinics, etc. The company offers its products through various delivery systems, such as glass and plastic bo...
Near Parimal Railway Crossing
Founded in 1994
Key Executives for Claris Lifesciences Limited
Vice Chairman, Managing Director, Member of Share Transfer Committee, Member of Executive Committee, Member of Corporate Social Responsibility Committee and Member of Stakeholders Relationship Committee
Total Annual Compensation: 6.0M
Chief Financial Officer, Whole Time Director, Member of Share Transfer Committee, Member of Executive Committee, Member of Audit Committee, Member of Corporate Social Responsibility Committee and Member of Stakeholders Relationship Committee
Total Annual Compensation: 9.7M
Senior Vice President, Compliance Officer and Company Secretary
Total Annual Compensation: 8.5M
Compensation as of Fiscal Year 2016.
Claris Lifesciences Limited Key Developments
Top PE Firms Reportedly Join Race For Claris Lifesciences’ US Business
Sep 30 16
Warburg Pincus LLC, Apax Partners LLP and The Blackstone Group L.P. (NYSE:BX) are in the race to acquire the US business of Claris Lifesciences Limited (BSE:533288). The business is expected to be valued at over $500 million and may also attract interest from a Chinese drugmaker and some Indian pharma companies, people familiar with the development told Economic Times. A Claris spokesperson told ET that the company does not comment on market speculation. “The company continues to evaluate various growth options from time to time and we will continue to update the stock exchanges if there is any definitive development, as required by regulations."
Claris Lifesciences Receives New Drug Application Approval for Flumazenil Injection USP
Aug 29 16
Claris Lifesciences has received an Abbreviated New Drug Application (ANDA) approval for Flumazenil Injection USP, 0.5mg/mL and 1mg/10mL multiple dose vials, in the United States of America. The ANDA approval has come for the same plant where the FDA had recently completed their Prior Approval Inspection (PAI). The estimated market size in the US is $4 million. With this approval, the company now has a total of 16 approvals and 23 under approval ANDAs, the total addressable market size of the approved ANDAs is estimated to be a little above $300 million.
Carlyle Group Reportedly Prepares Bid For Claris Lifesciences's Injectable Drugs Business
Aug 23 16
The Carlyle Group LP (NasdaqGS:CG) to bid for injectable drugs business of Claris Lifesciences Limited (BSE:533288). Carlyle Group to partner with a drug maker to acquire Claris's business that is valued at $400-450 million. Claris has hired Jefferies LLC and Credit Suisse Group AG (SWX:CSGN) to find a buyer for the business.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|